Literature DB >> 27391799

Astroglial connexin43 contributes to neuronal suffering in a mouse model of Alzheimer's disease.

C Yi1,2,3, X Mei1,2,3, P Ezan1,2,3, S Mato4,5, I Matias6,7, C Giaume1,2,3, A Koulakoff1,2,3.   

Abstract

In Alzheimer's disease (AD), astrocyte properties are modified but their involvement in this pathology is only beginning to be appreciated. The expression of connexins, proteins forming gap junction channels and hemichannels, is increased in astrocytes contacting amyloid plaques in brains of AD patients and APP/PS1 mice. The consequences on their channel functions was investigated in a murine model of familial AD, the APPswe/PS1dE9 mice. Whereas gap junctional communication was not affected, we revealed that hemichannels were activated in astrocytes of acute hippocampal slices containing Aβ plaques. Such hemichannel activity was detected in all astrocytes, whatever their distance from amyloid plaques, but with an enhanced activity in the reactive astrocytes contacting amyloid plaques. Connexin43 was the main hemichannel contributor, however, a minor pannexin1 component was also identified in the subpopulation of reactive astrocytes in direct contact with plaques. Distinct regulatory pathways are involved in connexin and pannexin hemichannel activation. Inflammation triggered pannexin hemichannel activity, whereas connexin43 hemichannels were activated by the increase in resting calcium level of astrocytes. Importantly, hemichannel activation led to the release of ATP and glutamate that contributed to maintain a high calcium level in astrocytes placing them in the center of a vicious circle. The astroglial targeted connexin43 gene knocking-out in APPswe/PS1dE9 mice allowed to diminish gliotransmitter release and to alleviate neuronal damages, reducing oxidative stress and neuritic dystrophies in hippocampal neurons associated to plaques. Altogether, these data highlight the importance of astroglial hemichannels in AD and suggest that blocking astroglial hemichannel activity in astrocytes could represent an alternative therapeutic strategy in AD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27391799      PMCID: PMC5041199          DOI: 10.1038/cdd.2016.63

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  60 in total

1.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.

Authors:  J L Jankowsky; H H Slunt; T Ratovitski; N A Jenkins; N G Copeland; D R Borchelt
Journal:  Biomol Eng       Date:  2001-06

2.  Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model.

Authors:  Andrea Delekate; Martina Füchtemeier; Toni Schumacher; Cordula Ulbrich; Marco Foddis; Gabor C Petzold
Journal:  Nat Commun       Date:  2014-11-19       Impact factor: 14.919

Review 3.  Non-junction functions of pannexin-1 channels.

Authors:  Brian A MacVicar; Roger J Thompson
Journal:  Trends Neurosci       Date:  2009-12-18       Impact factor: 13.837

Review 4.  Astrocytes in Alzheimer's disease.

Authors:  Alexei Verkhratsky; Markel Olabarria; Harun N Noristani; Chia-Yu Yeh; Jose Julio Rodriguez
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

5.  Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model.

Authors:  Sebastian Jimenez; Manuel Torres; Marisa Vizuete; Raquel Sanchez-Varo; Elisabeth Sanchez-Mejias; Laura Trujillo-Estrada; Irene Carmona-Cuenca; Cristina Caballero; Diego Ruano; Antonia Gutierrez; Javier Vitorica
Journal:  J Biol Chem       Date:  2011-04-01       Impact factor: 5.157

6.  Aβ leads to Ca²⁺ signaling alterations and transcriptional changes in glial cells.

Authors:  Ambra A Grolla; Gohar Fakhfouri; Giulia Balzaretti; Elena Marcello; Fabrizio Gardoni; Pier L Canonico; Monica DiLuca; Armando A Genazzani; Dmitry Lim
Journal:  Neurobiol Aging       Date:  2012-06-05       Impact factor: 4.673

7.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities.

Authors:  Xiangyou Hu; Qi Shi; Xiangdong Zhou; Wanxia He; Hong Yi; Xinghua Yin; Marla Gearing; Allan Levey; Riqiang Yan
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

Review 8.  Minocycline and neurodegenerative diseases.

Authors:  Hye-Sun Kim; Yoo-Hun Suh
Journal:  Behav Brain Res       Date:  2008-10-11       Impact factor: 3.332

9.  GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.

Authors:  Seonmi Jo; Oleg Yarishkin; Yu Jin Hwang; Ye Eun Chun; Mijeong Park; Dong Ho Woo; Jin Young Bae; Taekeun Kim; Jaekwang Lee; Heejung Chun; Hyun Jung Park; Da Yong Lee; Jinpyo Hong; Hye Yun Kim; Soo-Jin Oh; Seung Ju Park; Hyo Lee; Bo-Eun Yoon; YoungSoo Kim; Yong Jeong; Insop Shim; Yong Chul Bae; Jeiwon Cho; Neil W Kowall; Hoon Ryu; Eunmi Hwang; Daesoo Kim; C Justin Lee
Journal:  Nat Med       Date:  2014-06-29       Impact factor: 53.440

10.  Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer's disease.

Authors:  J I Nagy; W Li; E L Hertzberg; C A Marotta
Journal:  Brain Res       Date:  1996-04-22       Impact factor: 3.252

View more
  39 in total

Review 1.  Purinergic Modulation of Activity in the Developing Auditory Pathway.

Authors:  Sasa Jovanovic; Ivan Milenkovic
Journal:  Neurosci Bull       Date:  2020-10-11       Impact factor: 5.203

Review 2.  Therapeutic strategies targeting connexins.

Authors:  Dale W Laird; Paul D Lampe
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 3.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 4.  The role of connexin and pannexin containing channels in the innate and acquired immune response.

Authors:  Silvana Valdebenito; Andrea Barreto; Eliseo A Eugenin
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-05-27       Impact factor: 3.747

Review 5.  Brain Disorders and Chemical Pollutants: A Gap Junction Link?

Authors:  Marc Mesnil; Norah Defamie; Christian Naus; Denis Sarrouilhe
Journal:  Biomolecules       Date:  2020-12-31

6.  Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Authors:  Yeri Kim; Jarred M Griffin; Mohd N Mat Nor; Jie Zhang; Peter S Freestone; Helen V Danesh-Meyer; Ilva D Rupenthal; Monica Acosta; Louise F B Nicholson; Simon J O'Carroll; Colin R Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 7.  Connexin Hemichannels in Astrocytes: An Assessment of Controversies Regarding Their Functional Characteristics.

Authors:  Brian Skriver Nielsen; Daniel Bloch Hansen; Bruce R Ransom; Morten Schak Nielsen; Nanna MacAulay
Journal:  Neurochem Res       Date:  2017-04-22       Impact factor: 3.996

8.  Amyloid-β regulates gap junction protein connexin 43 trafficking in cultured primary astrocytes.

Authors:  Mahua Maulik; Lakshmy Vasan; Abhishek Bose; Saikat Dutta Chowdhury; Neelanjana Sengupta; Jayasri Das Sarma
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

Review 9.  Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs.

Authors:  Madeline Halpern; Kristen J Brennand; James Gregory
Journal:  Neurobiol Dis       Date:  2019-08-02       Impact factor: 5.996

10.  Connexin43 promotes angiogenesis through activating the HIF-1α/VEGF signaling pathway under chronic cerebral hypoperfusion.

Authors:  Weiwei Yu; Haiqiang Jin; Wei Sun; Ding Nan; Jianwen Deng; Jingjing Jia; Zemou Yu; Yining Huang
Journal:  J Cereb Blood Flow Metab       Date:  2021-04-25       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.